Clinical trials: Alopecia, Androgenetic
Androgenetic Alopecia
A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia
This trial aims to evaluate the efficacy, safety, and tolerability of fractional laser combined with topical exosome for hair regrowth in patients with androgenetic alopecia. This study is expected to recruit 30 participants.
- Trial name
- NCT07248410
- Testing
- fraction laser
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Androgenetic Alopecia
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
The study is designed to validate efficacy and long term safety of PP405.
- Trial name
- AWAKEN (NCT07819435)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Where
- 63 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Androgenetic Alopecia
Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial
The goal of this clinical trial is to learn whether botulinum toxin A (BTA) or autologous nanofat injection is more effective for treating male androgenetic alopecia. It will also assess the safety of both treatments.
- Trial name
- AGA (NCT07863856)
- Testing
- Botulinum Toxin Type A, Autologous Nanofat Injection
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Ayman Hussein Shaamash
Androgenetic Alopecia
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic…
- Trial name
- NCT02503137
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Biosplice Therapeutics, Inc.
Androgenetic Alopecia
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic…
- Trial name
- NCT03742518
- Testing
- Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 675 people
- Sponsor
- Biosplice Therapeutics, Inc.
Scarring Alopecia, Androgenetic Alopecia
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.
- Trial name
- NCT05460611
- Testing
- Sciton HALO 1470nm Non-ablative laser
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Androgenetic Alopecia, Cicatricial Alopecia
Evidence-Based Integrated Protocol to Maximize Hair Follicle Survival in Follicular Unit Extraction (FUE)
Follicular unit extraction (FUE) is a widely used surgical technique for hair restoration, yet hair follicle survival rates vary depending on surgical instrumentation, graft handling, and perioperative care.
- Trial name
- NCT07850011
- Testing
- Integrated Evidence-Based FUE Protocol, Standard FUE Practice
- Volunteers
- 30 people
- Sponsor
- Assiut University
Androgenetic Alopecia, Female Pattern Baldness
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
The goal of this clinical trial is to learn about oral minoxidil 1mg in the treatment of women with androgenetic alopecia, a type of hormone-imbalanced hair loss.
- Trial name
- NCT05888922
- Testing
- Minoxidil Tablets, Minoxidil Topical, Vehicle solution
- Where
- 27 sites in Germany, Italy and 2 more
- Volunteers
- 520 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Androgenetic Alopecia, Wound Healing
Topical Rifamycin SV for Wound Healing After Sapphire FUE Hair Transplantation
This prospective, parallel-group controlled clinical study evaluated whether a single topical rifamycin SV protocol added to standardized care after sapphire follicular unit extraction (FUE) was associated with earlier recorded…
- Trial name
- NCT07155408
- Testing
- Povidone-Iodine 10%, Rifamycin SV Sodium
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Elif Asena KANTARCI
Diabete Mellitus, Female Androgenetic Alopecia
Hair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic Examination
The aim of this thesis is to investigate the effect of diabetes mellitus on hair by assessing and comparing clinical and dermoscopic hair changes in diabetic patients versus age and sex-matched healthy controls.
- Conditions
- Diabete Mellitus, Female Androgenetic Alopecia, Dermoscopy
- Trial name
- TrichoscopyDM2 (NCT07817277)
- Where
- Egypt
- Volunteers
- 130 people
- Sponsor
- Al-Azhar University
Androgenetic Alopecia (AGA)
PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study
Research Purpose The objective of this study is to determine the safety and efficacy of combined PRP and BTX-A injection therapy for Androgenetic Alopecia (AGA).
- Trial name
- AGA (NCT07335367)
- Testing
- Injection of PRP combined with Botulinum Toxin Type A into the alopecic area(s), PRP-only injection into the alopecic area
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Alopecia, Androgenetic
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
- Trial name
- MONA (NCT07516561)
- Testing
- APSMNF 1, APSMNF 2, Eniagor®
- Where
- Brazil
- Volunteers
- 336 people
- Sponsor
- Apsen Farmaceutica S.A.
Androgenetic Alopecia
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
- Trial name
- NCT06916793
- Testing
- CKD-843 dose#1, CKD-843 dose#2, Dutasteride Capsules
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body…
- Trial name
- NCT07317544
- Testing
- SAD IV Dose 1 - 150mg ABS201 IV Single Dose, ABS-201 SC Multiple Doses
- Where
- 4 sites in Australia
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Absci Pty Ltd.
Androgenetic Alopecia, Exosomes
Exosome Injection Versus Topical Minoxidil for Androgenetic Alopecia
Androgenetic alopecia (AGA) is a common form of hair loss characterized by progressive hair follicle miniaturization. This prospective randomized comparative study evaluates the efficacy and safety of intradermal exosome…
- Trial name
- EXO-MINO (NCT07776015)
- Testing
- exosomes injection, Topical Minoxidil 5%
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Tanta University
Androgenetic Alopecia (AGA), Androgenetic Alopecia
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that…
- Conditions
- Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
- Trial name
- NCT07146022
- Testing
- VDPHL01 QD, VDPHL01 BID
- Where
- 71 sites in United States
- Volunteers
- 552 people
- Sponsor
- Veradermics, Inc.
Androgenetic Alopecia
XVIE to Treat Androgenetic Alopecia (AGA)
This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic alopecia (common pattern hair loss).
- Trial name
- NCT07482423
- Testing
- Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé